Brief: Sellas Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S Regal Trial To Continue Without Any Modifications
22/08/2023 13:37
Aug 22 (Reuters) -
* SELLAS LIFE SCIENCES INDEPENDENT DATA MONITORING COMMITTEE
RECOMMENDS GALINPEPIMUT-S REGAL TRIAL TO CONTINUE WITHOUT ANY
MODIFICATIONS
* SELLAS LIFE SCIENCES GROUP INC - REGAL INTERIM ANALYSIS
EXPECTED
BY LATE 2023/EARLY 2024
* SELLAS LIFE SCIENCES GROUP INC - ENROLLMENT EXPECTED TO BE
COMPLETED IN Q4 2023
* SELLAS LIFE SCIENCES GROUP INC - IDMC IS SCHEDULED TO MEET
AGAIN
WITHIN Q4 2023
Source text for Eikon: ID:nGNX1nDWP6
Further company coverage: SLS.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Sellas Life Sciences
See all newsBrief: Sellas Life Sciences Reaches 80Th Event In Phase 3 Regal Trial Of Galinpepimut-S (Gps) In Acute Myeloid Leukemia
SELLAS Life Sciences Q2 net loss widens on higher expenses
Brief: SELLAS Life Sciences Q2 Net Income USD -9.605 Million
Arbitrator Dismisses Company's Claims In Arbitration Against 3D Medicines On July 24, 2026 - SEC Filing
SELLAS Life Sciences Q1 net loss widens on higher expenses